Table I.
Patients’ characteristics
| PASI = 0 (n = 746) | PASI > 0-< 2 (n = 485) | PASI > 2-< 4 (n = 246) | PASI > 4 (n = 207) | p-value | |
|---|---|---|---|---|---|
| Male, n (%) | 476 (64.0) | 316 (65.3) | 168 (68.9) | 145 (70.7) | 0.26 |
| Psoriatic arthritis, n (%) | 250 (33.5) | 140 (28.9) | 83 (33.7) | 64 (30.9) | 0.33 |
| Methotrexate, n (%) | 65 (8.7) | 39 (8.0) | 28 (11.4) | 33 (15.9) | 0.0066 |
| Age, years, mean (SD) | 43.1 (14.7) | 43.9 (14.7) | 46.5 (14.4) | 46.2 (14.0) | 0.0028 |
| Weight, kg, mean (SD) | 87.1 (20.4) | 90.2 (19.8) | 91.2 (20.5) | 95.0 (22.8) | <0.0001 |
| Missing: 86 | Missing: 66 | Missing: 42 | Missing: 64 | ||
| Body max index, mean (SD) | 28.5 (6.7) | 30.1 (6.8) | 29.8 (6.4) | 31.4 (7.0) | <0.0001 |
| Missing: 190 | Missing: 132 | Missing: 64 | Missing: 83 | ||
| Disease duration, years, median (IQR) | 19.0 (11.5-28.0) | 19.8 (11.4-28.8) | 19.4 (11.6-27.0) | 19.5 (11.9-29.5) | 0.87* |
| Missing: 273 | Missing: 165 | Missing: 68 | Missing: 50 | ||
| Pretreatment PASI, median (IQR) | 11.0 (8.0-15.0) | 10.0 (6.8-14.0) | 12.0 (9.0-16.0) | 13.0 (10.0-19.0) | <0.0001* |
| Missing: 108 | Missing: 65 | Missing: 39 | Missing: 42 | ||
| Pretreatment DLQI, median (IQR) | 13.0 (8.0-18.0) | 12.0 (8.0-17.0) | 14.0 (8.0-19.0) | 12.0 (7.0-17.0) | 0.36* |
| Missing: 231 | Missing: 133 | Missing: 69 | Missing: 78 | ||
| Drugs, n (%) | |||||
| Adalimumab | 260 (34.9) | 182 (37.5) | 87 (35.4) | 70 (33.8) | 0.59 |
| Etanercept | 49 (6.6) | 55 (11.3) | 51 (20.7) | 61 (29.5) | <0.0001 |
| Infliximab | NS | NS | NS | NS | 0.46 |
| Ustekinumab | 227 (30.4) | 172 (35.5) | 90 (36.6) | 56 (27.0) | 0.045 |
| Secukinumab | 169 (22.7) | 47 (9.7) | 8 (3.3) | 6 (2.9) | <0.0001 |
| Other | NS | NS | NS | NS | 0.83 |
| Time to response, days, median (IQR) | 112 (91-158) | 112 (91-161) | 119 (91-175) | 97 (83-126) | <0.0001* |
| Achieving response after 3 months, n (%) | 493 (66.1) | 326 (67.2) | 136 (55.3) | 148 (71.5) | 0.0015 |
| Achieving response after 6 months, n (%) | 228 (30.6) | 144 (29.7) | 99 (40.2) | 36 (17.4) | <0.0001 |
| Flare (PASI > 3), n (%) | |||||
| Flare | 157 (21.1) | 142 (29.3) | 111 (45.1) | 87 (42.0) | |
| Stop treatment | 21 (14.8) | 22 (16.5) | 25 (24.8) | 29 (35.8) | 0.0010 |
| Return of PASI | 46 (32.4) | 43 (32.3) | 38 (37.6) | 18 (22.2) | 0.17 |
| Flare (PASI > 5), n (%) | |||||
| Flare | 64 (8.6) | 59 (12.2) | 55 (22.4) | 45 (21.7) | |
| Stop treatment | 10 (17.5) | 11 (20.0) | 15 (28.9) | 15 (36.6) | 0.12 |
| Return of PASI | 19 (33.3) | 17 (30.9) | 18 (34.6) | 10 (24.4) | 0.73 |
Outcomes are not shown where one group had < 3 patients.
*
Kruskal–Wallis test was used to assess differences in the groups.
PASI: Psoriasis Area and Severity Index; DLQI: Dermatology Life Quality Index; IQR: interquartile range; SD: standard deviation; NS: not shown due to data security requirements.